VBI recalls PreHevbrio and winds down operations

Massachusetts, USA-based firm VBI Vaccines (Nasdaq: VBIV) has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations.

The company has instructed healthcare providers and distributors to halt the distribution and administration of the product, which was approved by the US regulator in 2021.

This decision comes after VBI filed for bankruptcy in July, accompanied by a similar restructuring process in Canada. VBI had originally sought to undertake asset sales or investment opportunities, but has since pivoted to shutting down.